Background Disease-modifying treatments are in development for Huntington's disease;
crucial to their success is to identify a timepoint in a patient's life when there is a measurable …

The longitudinal dynamics of the most promising biofluid biomarker candidates for
Huntington’s disease (HD)—mutant huntingtin (mHTT) and neurofilament light (NfL)—are …

Objective Neurofilament light (NfL) protein in blood plasma has been proposed as a prognostic
biomarker of neurodegeneration in a number of conditions, including Huntington disease …

Objective Determining the sequence in which Huntington's disease biomarkers become
abnormal can provide important insights into the disease progression and a quantitative tool for …

… Author links open overlay panel Eileanoir B. Johnson a , Elin M. Rees a , Izelle … ))/(Surface
area region A+Surface area region B). This calculation accounts for different surface areas of …

Background Characterizing changing brain structure in neurodegeneration is fundamental to
understanding long-term effects of pathology and ultimately providing therapeutic targets. It …

Objectives: Visuospatial processing deficits have been reported in Huntington’s disease (HD).
To date, no study has examined associations between visuospatial cognition and …

Background and Objectives Longitudinal measurements of brain atrophy using structural
MRI (sMRI) can provide powerful markers for tracking disease progression in …

Objectives Cognitive flexibility, which is key for adaptive decision-making, engages prefrontal
cortex (PFC)-striatal circuitry and is impaired in both manifest and premanifest Huntington’…

The selection of an appropriate segmentation tool is a challenge facing any researcher
aiming to measure gray matter (GM) volume. Many tools have been compared, yet there is …